Tenax Therapeutics (NASDAQ:TENX) experienced a catastrophic market reaction on Monday, with shares plunging approximately 85% in premarket trading after the company announced that its Phase 3 LEVEL trial, evaluating oral levosimendan (TNX-103) for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), failed to achieve its primary efficacy endpoints.
As of 8:30 a.m. EDT, the stock was trading at $2.08, down 84.5% from Friday's close of $13.44, with premarket volume surging to 3.67 million shares—nearly double the previous full session's volume. The dramatic sell-off erased approximately $425 million in equity value, reducing the company's market capitalization to roughly $77.8 million based on 37.4 million shares outstanding, down from nearly $503 million at Friday's close.
Trial Results: Primary Endpoints Missed
The LEVEL study, which enrolled 241 patients across 41 sites in the U.S. and Canada, evaluated TNX-103 versus placebo over 12 weeks. The primary endpoint, change in 6-minute walk distance (6MWD), showed a placebo-adjusted improvement of only 3.5 meters (p=0.63), far below statistical significance. The least-squares mean increase was 14.0 meters for TNX-103 versus 10.4 meters for placebo.
The key secondary endpoint, the Kansas City Cardiomyopathy Questionnaire (KCCQ) total symptom score, also failed to show a meaningful difference, with an improvement of 6.6 points for TNX-103 versus 6.5 points for placebo—a negligible 0.1-point difference.
While a prespecified subgroup analysis of patients with baseline walk distance below the trial median of 333 meters showed a placebo-adjusted gain of 26.3 meters (nominal p=0.0112), Tenax management explicitly cautioned that these nominal p-values are not adjusted for multiple comparisons and do not constitute evidence of efficacy. The overall primary analysis's p-value of 0.63 underscores the trial's failure.
Exploratory Biomarker Signals
Despite the primary failure, exploratory biomarker analyses showed some positive trends. TNX-103 led to a 49% greater reduction in NT-proBNP compared to placebo (ratio 0.51, nominal p<0.0001) and a 3.5 mmHg reduction in estimated right-ventricular systolic pressure (nominal p=0.0045). However, these exploratory findings are not considered definitive.
Safety data revealed a higher incidence of adverse events in the treatment arm: 86.7% of TNX-103 patients reported any adverse event versus 71.9% for placebo, with treatment-related adverse events at 38.3% versus 17.4%. Serious adverse events were comparable (10.8% vs. 10.7%).
Regulatory Path and Future Plans
Tenax plans to request a Type C meeting with the U.S. Food and Drug Administration and seek input from the European Medicines Agency regarding potential enrichment of future trials with higher-disease-burden patients. The company's ongoing global LEVEL-2 trial remains the primary strategic focus, with management weighing options to modify the study, proceed as planned, or initiate further research pending regulatory feedback.
Full results from the LEVEL study will be presented at a late-breaking session at the European Society of Cardiology Congress in Munich on August 29.
Financial Position Amidst the Collapse
Despite the stock's collapse, Tenax's balance sheet provides some cushion. The company reported $118.0 million in cash as of June 30, plus an additional $8.1 million from post-quarter warrant exercises. This exceeds the current market capitalization, though on a fully diluted basis—including 19.9 million pre-funded warrants—the implied equity value is approximately $111.5 million, nearly matching cash levels.
The company's first-half operating cash use was $23.5 million (about $3.9 million per month), with a net loss of $33.5 million. Management had previously stated that existing funding would support operations through the second quarter of 2028.
Analysts note that cash does not serve as a strict valuation floor, especially given the substantial dilution from warrants and the uncertainty surrounding the LEVEL-2 trial's future direction. The market's severe reaction reflects the high expectations for levosimendan as a potential first-in-class therapy for PH-HFpEF, a condition with significant unmet medical need.
